JAGX

NASDAQ Healthcare

Jaguar Health, Inc. - Common Stock

Biotechnology

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

๐Ÿ“Š Market Data
Price$6.94
Volume1,389,598
Market Cap3.72M
Beta-0.060
RSI (14-Day)47.6
200-Day MA$194.22
50-Day MA$12.32
52-Week High$1281.00
52-Week Low$2.35
Forward P/E-1.26
Price / Book5.25
๐ŸŽฏ Investment Strategy Scores

JAGX scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
High growth potential (high beta + oversold)
Contrarian plays (oversold + below moving average)
Overbought stocks (potential short candidates)
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (99/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐Ÿš€ Moon Shot (4/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find JAGX in your text

Paste any article, transcript, or post โ€” the tool will extract JAGX and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.